Literature DB >> 19233403

Long-term followup of dextranomer/hyaluronic acid injection for vesicoureteral reflux: late failure warrants continued followup.

Eugene K Lee1, John M Gatti, Romano T Demarco, J Patrick Murphy.   

Abstract

PURPOSE: Dextranomer/hyaluronic acid injection of ureteral orifices is a popular option in the treatment of vesicoureteral reflux, with success rates ranging from 69% to 89%. We found only 1 study that followed patients beyond the initial postoperative voiding cystourethrogram, which describes a 96% success rate at 2 to 5 years but defines success as "nondilating" reflux. We examined our dextranomer/hyaluronic acid series to evaluate the long-term (1-year) outcome in children who had resolution of reflux on initial postoperative voiding cystourethrography.
MATERIALS AND METHODS: We retrospectively reviewed our dextranomer/hyaluronic acid experience from February of 2002 to December of 2005. We determined initial success on early (6 to 12-week) postoperative voiding cystourethrogram. We then evaluated long-term success by obtaining a voiding cystourethrogram at 1 year postoperatively in patients who were initially cured of reflux. In addition, success rates between the first and second halves of our experience were evaluated to account for surgeon experience and modification of technique.
RESULTS: Our total success rate at initial voiding cystourethrogram was 73% (246 of 337 total ureters). The success rate in the first half of our experience was 65.9% (112 of 170 ureters) and in the second half was 80.2% (134 of 167). A total of 150 ureteral units with initial successful dextranomer/hyaluronic acid treatment were evaluated at 1 year by voiding cystourethrogram. Of these ureters 111 had continued resolution of vesicoureteral reflux, for a long-term success rate of 74%. Including initial postoperative failures, the complete 1-year total success rate was 46.1% (111 of 241 ureters).
CONCLUSIONS: Although the reflux resolution rates at initial postoperative voiding cystourethrogram approach those of open surgery, there is a significant failure rate at 1 year, which warrants long-term followup.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233403     DOI: 10.1016/j.juro.2008.12.005

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  37 in total

Review 1.  [Therapeutic options for primary vesicoureteral reflux: endoscopic vs open surgical approach].

Authors:  C Ziesel; S Frees; J W Thüroff; R Stein
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Medical versus surgical management for vesicoureteric reflux: the case for medical management.

Authors:  Armando J Lorenzo
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

3.  Rebuttal.

Authors:  Armando J Lorenzo
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

4.  Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.

Authors:  Ellen Shapiro
Journal:  Rev Urol       Date:  2008

Review 5.  [Current and practice-relevant news from pediatric urology].

Authors:  R Stein; A Schröder; M Goepel
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

6.  Endoscopic treatment of vesicoureteral reflux: current practice and the need for multifactorial assessment.

Authors:  Göran Läckgren; Arne Stenberg
Journal:  Ther Adv Urol       Date:  2009-08

7.  Modified STING procedure for high-grade vesicoureteral reflux in children: intraureteral injection with ureteral orifice reposition technique.

Authors:  Takao Fujimoto; Tomohide Suwa; Nozomi Ishii
Journal:  Pediatr Surg Int       Date:  2012-08-03       Impact factor: 1.827

8.  Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR).

Authors:  L García-Aparicio; E Blázquez-Gómez; O Martin; S Pérez-Bertólez; J Arboleda; A Soria; X Tarrado
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

9.  Readmissions, unplanned emergency room visits, and surgical retreatment rates after anti-reflux procedures.

Authors:  Hsin-Hsiao S Wang; Rohit Tejwani; Steven Wolf; John S Wiener; Jonathan C Routh
Journal:  J Pediatr Urol       Date:  2017-04-07       Impact factor: 1.830

10.  Combination of calcium hydroxyapatite and autologous blood for endoscopic treatment of vesicoureteral reflux in children.

Authors:  Roozbeh Tanhaeivash; Abdol-Mohammad Kajbafzadeh; Atefeh Zeinoddini; Neda Khalili; Mona Vahidi Rad; Reza Heidari
Journal:  Int Urol Nephrol       Date:  2014-02-20       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.